Total Payments
$2,539
2023 Payments
$47.44
Companies
40
Transactions
112
Medicare Patients
3,953
Medicare Billing
$1.1M
Payment Breakdown by Category
Food & Beverage$2,448 (96.4%)
Education$91.39 (3.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,448 | 108 | 96.4% |
| Education | $91.39 | 4 | 3.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $299.23 | 6 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $259.80 | 4 | $0 (2019) |
| Amgen Inc. | $181.53 | 12 | $0 (2020) |
| Merck Sharp & Dohme Corporation | $138.36 | 10 | $0 (2020) |
| INSYS Therapeutics Inc | $122.82 | 7 | $0 (2017) |
| Varian Medical Systems, Inc. | $107.50 | 1 | $0 (2019) |
| Lilly USA, LLC | $94.92 | 4 | $0 (2020) |
| AUGMENIX, INC. | $93.64 | 1 | $0 (2017) |
| Regeneron Healthcare Solutions, Inc. | $93.11 | 4 | $0 (2021) |
| Eisai Inc. | $86.45 | 5 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $47.44 | 2 | Janssen Biotech, Inc. ($26.92) |
| 2022 | $41.79 | 2 | Biofrontera Inc. ($24.43) |
| 2021 | $169.51 | 6 | GENZYME CORPORATION ($60.11) |
| 2020 | $360.10 | 22 | Amgen Inc. ($115.12) |
| 2019 | $978.21 | 39 | GENZYME CORPORATION ($173.21) |
| 2018 | $512.67 | 26 | E.R. Squibb & Sons, L.L.C. ($132.35) |
| 2017 | $429.51 | 15 | INSYS Therapeutics Inc ($122.82) |
All Payment Transactions
112 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/21/2023 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $26.92 | General |
| Category: Immunology | ||||||
| 05/30/2023 | Biofrontera Inc. | AMELUZ (Drug), BF-RhodoLED, XEPI | Food and Beverage | Cash or cash equivalent | $20.52 | General |
| Category: DERMATOLOGY | ||||||
| 12/06/2022 | Biofrontera Inc. | AMELUZ (Drug), XEPI, BF-RhodoLED | Food and Beverage | Cash or cash equivalent | $24.43 | General |
| Category: DERMATOLOGY | ||||||
| 02/10/2022 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $17.36 | General |
| Category: Immunology | ||||||
| 11/18/2021 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $39.98 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/17/2021 | AbbVie Inc. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $22.13 | General |
| Category: ONCOLOGY | ||||||
| 08/12/2021 | TerSera Therapeutics LLC | Xermelo (Drug) | Food and Beverage | In-kind items and services | $20.48 | General |
| Category: Oncology | ||||||
| 08/11/2021 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), FEMARA, PIQRAY | Food and Beverage | In-kind items and services | $11.88 | General |
| Category: ONCOLOGY | ||||||
| 07/22/2021 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $14.93 | General |
| Category: ONCOLOGY | ||||||
| 04/20/2021 | GENZYME CORPORATION | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $60.11 | General |
| Category: Oncology | ||||||
| 12/11/2020 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Food and Beverage | In-kind items and services | $22.35 | General |
| Category: Oncology | ||||||
| 11/19/2020 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $13.31 | General |
| Category: Oncology | ||||||
| 11/17/2020 | Genentech USA, Inc. | VENCLEXTA (Biological) | Food and Beverage | In-kind items and services | $17.46 | General |
| Category: BioOncology | ||||||
| 11/02/2020 | GENZYME CORPORATION | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Oncology | ||||||
| 10/12/2020 | Amgen Inc. | XGEVA (Biological) | Food and Beverage | In-kind items and services | $18.58 | General |
| Category: Oncology | ||||||
| 10/05/2020 | Amgen Inc. | KANJINTI (Biological), MVASI, Neulasta | Food and Beverage | In-kind items and services | $12.25 | General |
| Category: Oncology | ||||||
| 09/11/2020 | Amgen Inc. | KANJINTI (Biological), MVASI, Neulasta | Food and Beverage | In-kind items and services | $12.27 | General |
| Category: Oncology | ||||||
| 08/19/2020 | Jazz Pharmaceuticals Inc. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $16.21 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 08/09/2020 | AbbVie Inc. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $17.82 | General |
| Category: ONCOLOGY | ||||||
| 08/06/2020 | Amgen Inc. | Prolia (Biological), XGEVA | Food and Beverage | In-kind items and services | $21.94 | General |
| Category: Bone Health | ||||||
| 08/05/2020 | Amgen Inc. | Vectibix (Biological) | Food and Beverage | In-kind items and services | $8.74 | General |
| Category: Oncology | ||||||
| 07/13/2020 | Amgen Inc. | Blincyto (Biological) | Food and Beverage | In-kind items and services | $9.38 | General |
| Category: Oncology | ||||||
| 06/23/2020 | Amgen Inc. | Vectibix (Biological) | Food and Beverage | In-kind items and services | $13.44 | General |
| Category: Oncology | ||||||
| 06/16/2020 | Amgen Inc. | Prolia (Biological), XGEVA | Food and Beverage | In-kind items and services | $18.52 | General |
| Category: Bone Health | ||||||
| 02/26/2020 | Eisai Inc. | Lenvima (Drug), Halaven | Food and Beverage | Cash or cash equivalent | $13.11 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 984 | 2,172 | $598,885 | $291,986 |
| 2022 | 9 | 1,135 | 2,366 | $659,983 | $332,775 |
| 2021 | 15 | 922 | 1,987 | $848,528 | $224,395 |
| 2020 | 14 | 912 | 1,924 | $917,329 | $261,214 |
Total Patients
3,953
Total Services
8,449
Medicare Billing
$1.1M
Procedure Codes
61
All Medicare Procedures & Services
61 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 77280 | Obtaining data needed to develop the optimal radiation treatment, 1 treatment area | Office | 2023 | 132 | 552 | $206,901 | $106,895 | 51.7% |
| 77285 | Obtaining data needed to develop the optimal radiation treatment, 2 treatment areas | Office | 2023 | 44 | 194 | $119,217 | $60,909 | 51.1% |
| 77427 | Radiation treatment management, 5 treatment sessions | Office | 2023 | 141 | 240 | $65,380 | $34,241 | 52.4% |
| 77290 | Obtaining data needed to develop the optimal radiation treatment, 3 or more treatment areas or any number of treatment areas where special treatment is involved | Office | 2023 | 98 | 99 | $62,528 | $31,918 | 51.0% |
| G6001 | Ultrasonic guidance for placement of radiation therapy fields | Office | 2023 | 104 | 148 | $37,229 | $19,459 | 52.3% |
| 77401 | Superficial and/or low voltage radiation treatment delivery | Office | 2023 | 158 | 515 | $29,154 | $15,151 | 52.0% |
| 77300 | Calculation of radiation therapy dose | Office | 2023 | 115 | 171 | $15,877 | $8,208 | 51.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 99 | 100 | $12,768 | $6,268 | 49.1% |
| 77427 | Radiation treatment management, 5 treatment sessions | Facility | 2023 | 37 | 40 | $31,208 | $5,179 | 16.6% |
| 77014 | Ct guidance for insertion of radiation therapy fields | Facility | 2023 | 26 | 82 | $13,530 | $2,563 | 18.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 18 | 19 | $3,060 | $871.06 | 28.5% |
| 77280 | Obtaining data needed to develop the optimal radiation treatment, 1 treatment area | Facility | 2023 | 12 | 12 | $2,033 | $323.67 | 15.9% |
| 77280 | Obtaining data needed to develop the optimal radiation treatment, 1 treatment area | Office | 2022 | 196 | 687 | $257,206 | $131,383 | 51.1% |
| 77285 | Obtaining data needed to develop the optimal radiation treatment, 2 treatment areas | Office | 2022 | 71 | 222 | $137,400 | $71,674 | 52.2% |
| 77290 | Obtaining data needed to develop the optimal radiation treatment, 3 or more treatment areas or any number of treatment areas where special treatment is involved | Office | 2022 | 124 | 130 | $83,144 | $43,354 | 52.1% |
| 77427 | Radiation treatment management, 5 treatment sessions | Office | 2022 | 175 | 278 | $75,635 | $39,888 | 52.7% |
| 77401 | Superficial and/or low voltage radiation treatment delivery | Office | 2022 | 244 | 634 | $35,999 | $18,980 | 52.7% |
| 77300 | Calculation of radiation therapy dose | Office | 2022 | 131 | 178 | $16,335 | $8,622 | 52.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 91 | 92 | $16,785 | $8,447 | 50.3% |
| 77427 | Radiation treatment management, 5 treatment sessions | Facility | 2022 | 27 | 34 | $22,678 | $4,945 | 21.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 41 | 41 | $5,333 | $2,761 | 51.8% |
| 77014 | Ct guidance for insertion of radiation therapy fields | Facility | 2022 | 18 | 52 | $7,020 | $1,796 | 25.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 17 | 18 | $2,447 | $924.86 | 37.8% |
| 77285 | Management of radiation therapy, simulation, intermediate | Office | 2021 | 63 | 159 | $103,915 | $53,267 | 51.3% |
| 77280 | Management of radiation therapy simulation, simple | Office | 2021 | 101 | 242 | $95,325 | $50,139 | 52.6% |
About Dr. John Marvel, MD
Dr. John Marvel, MD is a Radiation Oncology healthcare provider based in Logansport, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/21/2005. The National Provider Identifier (NPI) number assigned to this provider is 1265432173.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Marvel, MD has received a total of $2,539 in payments from pharmaceutical and medical device companies, with $47.44 received in 2023. These payments were reported across 112 transactions from 40 companies. The most common payment nature is "Food and Beverage" ($2,448).
As a Medicare-enrolled provider, Marvel has provided services to 3,953 Medicare beneficiaries, totaling 8,449 services with total Medicare billing of $1.1M. Data is available for 4 years (2020–2023), covering 61 distinct procedure/service records.
Ad
Practice Information
- Specialty Radiation Oncology
- Location Logansport, IN
- Active Since 07/21/2005
- Last Updated 02/14/2008
- Taxonomy Code 2085R0001X
- Entity Type Individual
- NPI Number 1265432173
Products in Payments
- JEVTANA (Drug) $300.51
- OPDIVO (Biological) $247.79
- SUBSYS (Drug) $122.82
- Treatment Planning Systems (Device) $107.50
- KEYTRUDA (Biological) $100.77
- SpaceOAR (Device) $93.64
- DORYX (Drug) $77.59
- VPRIV (Biological) $76.32
- TAGRISSO (Drug) $70.77
- Kyprolis (Biological) $66.41
- INJECTAFER (Drug) $60.56
- DUPIXENT (Biological) $56.52
- VERZENIO (Drug) $53.48
- Lenvima (Drug) $48.65
- AMELUZ (Drug) $44.95
- TREMFYA (Drug) $44.28
- Xermelo (Drug) $42.42
- Imbruvica (Drug) $40.65
- Prolia (Biological) $40.46
- VENCLEXTA (Drug) $39.95
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.